Dendritic cell-based immunotherapy (DCVAC/OvCa) withchemotherapy in patients with platinum-sensitive, relapsed,epithelial ovarian carcinoma: Survival analysis of a phase II,open-label, randomized, multicenter trial (study SOV02)

CIBULA, D., ROB, L., MALLMANN, P., KNAPP, P., BARTŮŇKOVÁ, J., SPÍŠEK, R., HASSAN, H. I., PECEN, L., KLAT, J., CHOVANEC, J. Dendritic cell-based immunotherapy (DCVAC/OvCa) withchemotherapy in patients with platinum-sensitive, relapsed,epithelial ovarian carcinoma: Survival analysis of a phase II,open-label, randomized, multicenter trial (study SOV02). Gynecologic Oncology. 2019, 154(suppl. 1), 18-18. ISSN 0090-8258. E-ISSN 1095-6859. Available: doi: 10.1016/j.ygyno.2019.04.046